Signe Mosegaard

726 total citations
9 papers, 207 citations indexed

About

Signe Mosegaard is a scholar working on Clinical Biochemistry, Molecular Biology and Rheumatology. According to data from OpenAlex, Signe Mosegaard has authored 9 papers receiving a total of 207 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Clinical Biochemistry, 6 papers in Molecular Biology and 2 papers in Rheumatology. Recurrent topics in Signe Mosegaard's work include Metabolism and Genetic Disorders (7 papers), Mitochondrial Function and Pathology (4 papers) and Biochemical and Molecular Research (3 papers). Signe Mosegaard is often cited by papers focused on Metabolism and Genetic Disorders (7 papers), Mitochondrial Function and Pathology (4 papers) and Biochemical and Molecular Research (3 papers). Signe Mosegaard collaborates with scholars based in Denmark, Netherlands and Belgium. Signe Mosegaard's co-authors include Rikke Katrine Jentoft Olsen, Niels Gregersen, Peter Bross, Trine Tangeraas, Yngve Thomas Bliksrud, Maja Dembić, Brage Storstein Andresen, Gitte Hoffmann Bruun, Anders Paetau and Tiina Tyni and has published in prestigious journals such as The FASEB Journal, International Journal of Molecular Sciences and EMBO Molecular Medicine.

In The Last Decade

Signe Mosegaard

7 papers receiving 203 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Signe Mosegaard Denmark 5 111 99 57 49 31 9 207
Monique Albersen Netherlands 12 154 1.4× 109 1.1× 122 2.1× 50 1.0× 39 1.3× 17 292
Berit Woldseth Norway 10 81 0.7× 149 1.5× 13 0.2× 38 0.8× 52 1.7× 20 253
Nishitha R. Pillai United States 8 65 0.6× 109 1.1× 30 0.5× 26 0.5× 15 0.5× 28 264
Carmen Rohde Germany 11 241 2.2× 136 1.4× 55 1.0× 174 3.6× 25 0.8× 15 253
Sebastiano Giuffrida Italy 9 50 0.5× 39 0.4× 15 0.3× 45 0.9× 10 0.3× 23 538
Erika Ogawa Japan 8 111 1.0× 154 1.6× 20 0.4× 15 0.3× 8 0.3× 20 227
Sally T. Gleason United States 7 314 2.8× 162 1.6× 61 1.1× 266 5.4× 47 1.5× 8 381
Stefan Koelker Germany 3 214 1.9× 142 1.4× 26 0.5× 39 0.8× 79 2.5× 3 272
Elizabeth A. Donald United States 9 56 0.5× 80 0.8× 73 1.3× 61 1.2× 22 0.7× 16 318
Adrya Stembridge United States 5 287 2.6× 155 1.6× 60 1.1× 110 2.2× 29 0.9× 8 323

Countries citing papers authored by Signe Mosegaard

Since Specialization
Citations

This map shows the geographic impact of Signe Mosegaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Signe Mosegaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Signe Mosegaard more than expected).

Fields of papers citing papers by Signe Mosegaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Signe Mosegaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Signe Mosegaard. The network helps show where Signe Mosegaard may publish in the future.

Co-authorship network of co-authors of Signe Mosegaard

This figure shows the co-authorship network connecting the top 25 collaborators of Signe Mosegaard. A scholar is included among the top collaborators of Signe Mosegaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Signe Mosegaard. Signe Mosegaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Langeveld, Mirjam, et al.. (2025). Metabolic cardiomyopathies: untangling clinical heterogeneity with human stem-cell derived models. EMBO Molecular Medicine. 17(11). 2853–2874.
2.
Schomakers, Bauke V., Peter T. Simpson, Michel van Weeghel, et al.. (2025). Integrated multi-omics mapping of mitochondrial dysfunction and substrate preference in Barth syndrome cardiac tissue. EMBO Molecular Medicine. 17(11). 3227–3246.
3.
Mosegaard, Signe, Simone Denis, Jeffrey Kroon, et al.. (2024). Human inborn errors of long‐chain fatty acid oxidation show impaired inflammatory responses to TLR4 ‐ligand LPS. FASEB BioAdvances. 6(9). 337–350. 3 indexed citations
4.
Mosegaard, Signe, Suzan J. G. Knottnerus, Jan B. van Klinken, et al.. (2024). Tracer‐based lipidomics enables the discovery of disease‐specific candidate biomarkers in mitochondrial β‐oxidation disorders. The FASEB Journal. 38(4). e23478–e23478. 6 indexed citations
5.
Veiga‐da‐Cunha, Maria, Jakob Hansen, Margrethe Kjeldsen, et al.. (2021). Variants in the ethylmalonyl‐CoA decarboxylase (ECHDC1) gene: a novel player in ethylmalonic aciduria?. Journal of Inherited Metabolic Disease. 44(5). 1215–1225. 4 indexed citations
6.
Mosegaard, Signe, et al.. (2020). Riboflavin Deficiency—Implications for General Human Health and Inborn Errors of Metabolism. International Journal of Molecular Sciences. 21(11). 3847–3847. 117 indexed citations
7.
Muru, Kai, Karit Reinson, Zahra Nochi, et al.. (2019). FLAD1‐associated multiple acyl‐CoA dehydrogenase deficiency identified by newborn screening. Molecular Genetics & Genomic Medicine. 7(9). e915–e915. 13 indexed citations
8.
Auranen, Mari, Anders Paetau, Päivi Piirilä, et al.. (2017). Patient with multiple acyl-CoA dehydrogenation deficiency disease and FLAD1 mutations benefits from riboflavin therapy. Neuromuscular Disorders. 27(6). 581–584. 22 indexed citations
9.
Mosegaard, Signe, Gitte Hoffmann Bruun, Yngve Thomas Bliksrud, et al.. (2017). An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Molecular Genetics and Metabolism. 122(4). 182–188. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monique Albersen Breakdown of academic impact, for papers by Berit Woldseth Breakdown of academic impact, for papers by Nishitha R. Pillai Breakdown of academic impact, for papers by Carmen Rohde Breakdown of academic impact, for papers by Sebastiano Giuffrida Breakdown of academic impact, for papers by Erika Ogawa Breakdown of academic impact, for papers by Sally T. Gleason Breakdown of academic impact, for papers by Stefan Koelker Breakdown of academic impact, for papers by Elizabeth A. Donald Breakdown of academic impact, for papers by Adrya Stembridge
Rankless by CCL
2026